ACE2 and COVID-19: The protective effects of ACEI/ARBs were possibly driven, to some degree, by antiinflammatory effects in COVID-19 patients,15,16 specifically by inhibiting ACE2 downregulation-induced hyperactivation of the RAAS caused by the SARS-CoV-2 virus.7